Sandoz strikes deal with EirGenix for Herceptin biosimilar

09:00 EDT 30 Apr 2019 | pharmaphorum

Sandoz has struck a deal with Taiwan-based EirGenix to market a late-stage biosimilar of Roche’s breast cancer blockbuster Herceptin. The Novartis unit is playing catch-up with a gang of companies who already have their cheaper near-copies of Herc...

Original Article: Sandoz strikes deal with EirGenix for Herceptin biosimilar


More From BioPortfolio on "Sandoz strikes deal with EirGenix for Herceptin biosimilar"

Quick Search

Relevant Topics

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...